DRUG
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
Status
Completed
Phase
Phase 2
Enrollment
124
Locations
36
Results
Posted
Publications
0
Study summary
What the protocol is testing.
This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to \< 18 years diagnosed with Chronic Idiopathic Constipation.
Full detailed description
The purpose of the study is to evaluate efficacy, safety, and pharmacokinetics (PK) of oral Plecanatide 0.5, 1.0 and 1.5 mg tablets dosed once a day as compared to matching placebo, when administered for 8 weeks in adolescents with chronic idiopathic constipation. This study will consist of a 4-week screening period, 8 weeks of treatment, and a 2-week follow-up. The study will assess the effects of Plecanatide on bowel movement frequency and other clinical features of CIC.
Interventions
Treatment arms and agents.
DRUG
Matching placebo
Timeline
From registration to results.
First posted
Apr 19, 2017
Study start
Jan 2017
Primary completion
Sep 7, 2018
Study completion
Sep 7, 2018
Results posted
Sep 19, 2019
Registry updated
Oct 4, 2019
Outcomes
What the study measures.
Primary outcomes
Proportion of Overall Responders
Time frame · 8 weeks
An Overall Responder is a participant who was a Spontaneous Bowel Movement (SBM) responder for the last 2 weeks of the Treatment Period. An SBM responder is defined as a participant who had \>3 SBMs per week. SBM was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. Participants missing with respect to the outcome measure were scored as non-responders.
Secondary outcomes
Change From Baseline in Weekly Average Stool Consistency Bristol Stool Form Scale (BSFS) Score
Time frame · 8 weeks
Stool consistency was assessed via the 7-point (1-7) Bristol Stool Form Scale (BSFS) and recorded in the bowel movement (BM) and Symptom Diaries. Lower numbers represent more formed stools; higher numbers represent less formed stools. The weekly mean BSFS score per patient = (total of all BSFS scores reported for a corresponding Spontaneous Bowel Movement (SBM) per time period)/n, where n = number of SBMs scored during the time period. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS types were 1) separate hard lumps, like nuts (hard to pass); 2) sausage-shaped but lumpy; 3) like a sausage but with cracks on its surface; 4) like a sausage or snake, smooth and soft; 5) soft blobs with clear-cut edges (passed easily); 6) fluffy pieces with ragged edges, a mushy stool; 7) watery, no solid pieces, entirely liquid.
Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements (SBM)
Time frame · 8 weeks
The weekly Spontaneous Bowel Movement (SBM) totals were derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. SBM is defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours
Change From Baseline in the Weekly Rate of Complete Spontaneous Bowel Movements (CSBM)
Time frame · 8 weeks
The weekly Complete Spontaneous Bowel Movement (CSBM) totals are derived from the daily diary entries reported during the Treatment Period in the Bowel Movement (BM) and symptom diaries. Baseline is the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. Spontaneous Bowel Movement (SBM) was defined as a bowel movement that occurs in the absence of laxative use within the preceding 24 hours. CSBM was defined as a spontaneous bowel movement with the sense of complete evacuation.
Eligibility
Who can take part.
- Minimum age
- 12 Years
- Maximum age
- 17 Years
- Sex
- ALL
- Healthy volunteers
- No
Key Inclusion Criteria: 1. Male or female adolescents 12 to less than 18 years of age. 2. Diagnosed with CIC based on the Rome III criteria for child/adolescent functional constipation (Appendix A). 3. Patient is able to voluntarily provide written, signed, and dated (personally and via a legally authorized representative \[LAR\]) assent/informed consent as applicable to participate in the study. 4. Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures (e.g., accept venipuncture, willing and able to swallow tablets, accept urine drug screen for opiates) and restrictions. Key Exclusion Criteria: 1. The patient has a mental age \<4 years in the investigator's opinion. 2. The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation. 3. The patient currently requires iron supplements, amitriptyline, or other tricyclic antidepressants for depression, opioid-containing medications or compounds for pain, or has other conditions that require medications known to cause constipation. A patient with an onset of constipation prior to the use of these medications and who has been on a stable dose for at least 8 weeks prior to Screening might be considered eligible for this study if the investigator deems these medications do not significantly contribute to the patient's constipation. Screening of these patients needs to be approved by the medical monitor and the sponsor. 4. The patient, if female of childbearing potential (defined as postmenarche), does not agree to practice 1 of the following medically acceptable methods of birth control throughout the study: * Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before study drug administration. * Total abstinence from sexual intercourse since the last menses before study drug administration. * Intrauterine device. * Double barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream. 5. The patient follows a diet not considered normal by the investigator for the patient's age, relative to variety of food, caloric content, and quantity. The patient must have been on a stable diet for at least 30 days weeks prior to Screening. 6. The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion. 7. The patient has a history of an eating disorder.
Study locations
36 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Synergy Research Site
Foley, Alabama, United States
Synergy Research Site
Jonesboro, Arkansas, United States
Synergy Research Site
Cerritos, California, United States
Synergy Research Site
Corona, California, United States
Synergy Research Site
Downey, California, United States
Synergy Research Site
Huntington Beach, California, United States
Synergy Research Site
Sacramento, California, United States
Synergy Research Site
Ventura, California, United States
Synergy Research Site
Wilmington, Delaware, United States
Synergy Research Site
DeLand, Florida, United States
Synergy Research Site
Doral, Florida, United States
Synergy Research Site
Hialeah, Florida, United States
Synergy Research Site
Miami, Florida, United States
Synergy Research Site
Orlando, Florida, United States
Synergy Research Site
Tampa, Florida, United States
Synergy Research Site
Snellville, Georgia, United States
Synergy Research Site
Thomaston, Georgia, United States
Synergy Research Site
Idaho Falls, Idaho, United States
Synergy Research Site
Meridian, Idaho, United States
Synergy Research Site
Nicholasville, Kentucky, United States
Synergy Research Site
Crowley, Louisiana, United States
Synergy Research Site
Bellevue, Nebraska, United States
Synergy Research Site
Omaha, Nebraska, United States
Synergy Research Site
Fayetteville, North Carolina, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Plecanatide.
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Bausch Health Americas, Inc. · Functional Constipation (FC)
Phase 2
Active, not recruiting
180
2026-07
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
Bausch Health Americas, Inc. · Irritable Bowel Syndrome With Constipation
Phase 2
Completed
218
2025-12
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Functional Constipation
Phase 3
Completed
648
2024-07
Long Term Safety Study of Plecanatide
Bausch Health Americas, Inc. · Irritable Bowel Syndrome
Phase 3
Completed
2,272
2020-08
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 2
Completed
84
2020-01
12-Week Study of Plecanatide for CIC (The CIC3 Study)
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 3
Completed
1,394
2019-12
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Not applicable
Completed
7
2019-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.